The results announced in the Lancet Neurology are positive and support the potential of using INBRIJA™ as a treatment alternative. Levodopa is in ... read more
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Announces Publication Of Third Phase Results ...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Announces Publication Of Third Phase Results …